Session » Vasculitis – ANCA-Associated Poster II

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

Abstract Number: 1661

Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis

Abstract Number: 1662

Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?

Abstract Number: 1663

Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis

Abstract Number: 1664

Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial

Abstract Number: 1665

Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections

Abstract Number: 1666

Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems

Abstract Number: 1667

Long Term Outcome of Hydralazine-Associated Vasculitis

Abstract Number: 1668

Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry

Abstract Number: 1669

Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis

Abstract Number: 1670

Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)

Abstract Number: 1671

Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis

Abstract Number: 1672

Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018

Abstract Number: 1673

Factors Associated with Overall and First-Year Mortality in Turkish Patients with ANCA-Associated Vasculitides: Retrospective, Multicentre Trial

Abstract Number: 1674

Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience

Abstract Number: 1675

A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis

Abstract Number: 1676

Does Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Prevent Hospitalizations for Other Infections in Vasculitis Patients?

Abstract Number: 1677

Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?

Abstract Number: 1678

Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis

Abstract Number: 1679

Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Abstract Number: 1680

Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Abstract Number: 1681

The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)

Abstract Number: 1682

Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States

Abstract Number: 1683

Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort

Abstract Number: 1684

Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.